GlassScriptPhysician profile
Aftab A Khan
NPI 1811922099
$5,196.38
in general payments reported to CMS, 2019-2025
36 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what 96% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $512 · 2021: $871 · 2022: $787 · 2023: $419 · 2024: $1,194 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,867.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $963.81 | 2019-2025 | Wegovy, Ozempic |
| Vanda Pharmaceuticals INC. | $508.11 | 2020-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $491.61 | 2020-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $363.63 | 2023-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $317.26 | 2024 | Voquezna |
| Merz Pharmaceuticals, LLC | $297.70 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Otsuka America Pharmaceutical, INC. | $191.53 | 2021-2024 | Rexulti |
| Abbvie INC. | $171.68 | 2021-2024 | |
| Csl Behring | $159.76 | 2024-2025 | Hizentra |
| Amgen INC. | $146.23 | 2020-2024 | Uplizna |
| Lilly USA, LLC | $140.63 | 2022-2025 | Mounjaro |
| Jazz Pharmaceuticals INC. | $138.72 | 2024-2025 | |
| Melinta Therapeutics, LLC | $124.98 | 2024 | Rezzayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.80 | 2024 | Jardiance |
| Esperion Therapeutics, INC. | $105.80 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $91.03 | 2024-2025 | Rystiggo, Zilbrysq |
| Idorsia Pharmaceuticals US INC | $84.55 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $84.03 | 2022-2025 | Auvelity |
| Pfizer INC. | $79.25 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $71.47 | 2020-2022 | |
| Adlon Therapeutics L.P. | $59.74 | 2019-2020 | |
| Tris Pharma INC | $55.07 | 2023-2025 | Dyanavel Xr |
| Lundbeck LLC | $54.89 | 2021 | |
| Alexion Pharmaceuticals, INC. | $52.75 | 2025 | Ultomiris |
| Alkermes, INC. | $49.03 | 2022-2023 | Aristada, Lybalvi |
| Eisai INC. | $44.91 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.82 | 2022 | |
| Merck Sharp & Dohme LLC | $32.66 | 2022-2023 | Belsomra |
| Sunovion Pharmaceuticals INC. | $30.75 | 2019 | |
| Avanir Pharmaceuticals, INC. | $28.09 | 2019 | |
| Ironshore Pharmaceuticals INC. | $24.66 | 2019 | |
| Neos Therapeutics, LP | $21.71 | 2019 | |
| Neurocrine Biosciences, INC. | $21.66 | 2023 | Ingrezza |
| Allergan, INC. | $14.24 | 2019 | |
| Amarin Pharma, INC. | $12.74 | 2020 | |
| Supernus Pharmaceuticals, INC. | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aftab Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.